NASDAQ · Biotechnology · USD
ProMIS Neurosciences, Inc. (PMN) Stock Analysis
ProMIS Neurosciences, Inc. (PMN) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.
Last Updated: October 21, 2026
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
PMN Key Statistics
As of Oct 21, 2026Trading
- Open
- $8.18
- Previous Close
- $8.09
- Day's Range
- 8.18–9.13
- 52-Week Range
- 6.27–27.40
- Volume
- 7.49K
- BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
- −0.25
Valuation
- Market Cap
- $81.88M
- P/E Ratio
- unprofitable
- EPS (ttm)Profit attributable to each share over the last twelve months.
- −11.65
Financials (FY)
- Revenue (FY)
- $0.00
- Net Income (FY)
- −$39.72M−1,529.33%
- Shares Outstanding
- 8.97M
- 1-Year Return
- −17.00%
Dividend and dates
- Earnings Date
- November 13, 2026estimated
- Avg Volume
- 68.73K
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
Key facts
As of October 21, 2026, PMN closed at $9.13, −17.00% over 1 year.
ProMIS Neurosciences, Inc. (PMN) has a market capitalization of $81.88M.
In fiscal 2025, PMN reported revenue of $0.00.
PMN Stock Return by Calendar Year
ProMIS Neurosciences, Inc. (PMN) 10-year return: what $10,000 became
- 1 year
- $10,000 $8,300
- −17.00%
- 5 years
- $10,000 $406
- −95.94%
- 10 years
- $10,000 $609
- −93.91%
If you had invested $10,000 in ProMIS Neurosciences, Inc. (PMN) 10 years ago, at the close on October 21, 2016, it would have been worth $609 at the close on October 21, 2026: −93.91% in total, −24.41% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.
Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.
| Year | Return |
|---|---|
| 2026 (partial year) | +33.67% |
| 2025 | −71.24% |
| 2024 | −17.39% |
| 2023 | −73.50% |
| 2022 | −34.24% |
| 2021 | +37.50% |
| 2020 | −38.46% |
| 2019 | −35.00% |
| 2018 | +17.65% |
| 2017 | +70.00% |
| 2016 (partial year) | −9.09% |
As of October 21, 2026.
PMN Revenue and Earnings by Fiscal Year
FY ends December| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2025 | $0.00 | −$39.72M | — |
| 2024 | $0.00 | $2.78M | — |
| 2023 | $0.00 | −$13.21M | — |
| 2022 | $0.00 | −$18.06M | — |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2025 | $0.00 | — | −$40.17M | −$39.72M | — |
| 2024 | $0.00 | — | −$16.83M | $2.78M | — |
| 2023 | $0.00 | — | −$14.26M | −$13.21M | — |
| 2022 | $0.00 | — | −$23.38M | −$18.06M | — |
Annual figures as reported, in the company's reporting currency. As of December 31, 2025.
Recent News
ProMIS Neurosciences Appoints Seasoned Alzheimer’s and Neuroscience Executive Ivana Rubino, Ph.D., as Chief Commercial Officer
YahooProMIS Neurosciences to Participate in Upcoming Conferences and Events in September
YahooGuggenheim Maintains Buy on ProMIS Neurosciences, Raises Price Target to $100
BenzingaProMIS Neurosciences Reports Q2 2026 Results: Full Earnings Call Transcript
BenzingaProMIS Neurosciences Q2 EPS $(1.28) Beats $(1.38) Estimate
BenzingaGuggenheim Maintains Buy on ProMIS Neurosciences, Raises Price Target to $69
Benzinga
All 10 articles ↓Show fewer ↑
Small-Cap ProMIS Neurosciences Says Lead Drug Shows Encouraging Action in Early Alzheimer's Study
BenzingaChardan Capital Maintains Buy on ProMIS Neurosciences, Raises Price Target to $33
BenzingaProMIS Neurosciences Announces Six-Month Interim Safety And Biomarker Results From Its PRECISE-AD Phase 1B Trial Of PMN310 In Patients With Mild Cognitive Impairment Due To Alzheimer’s; Early Biomarker Movement Consistent With Target Engagement
BenzingaChardan Capital Initiates Coverage On ProMIS Neurosciences with Buy Rating, Announces Price Target of $20
Benzinga
News provided by third-party sources. Not financial advice.
Analysis
Data-derivedEvery figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.
Related Biotechnology Stocks
Vertex Pharmaceuticals Incorporated
$132.95B
MRNAModerna, Inc.
$98.14B
REGNRegeneron Pharmaceuticals, Inc.
$82.95B
ARGXargenx SE
$55.97B
ONCBeOne Medicines AG
$43.97B
RVMDRevolution Medicines, Inc.
$41.64B
Popular Healthcare Stocks
Eli Lilly and Company
$1.13T
JNJJohnson & Johnson
$621.22B
ABBVAbbVie Inc.
$503.27B
UNHUnitedHealth Group Incorporated
$374.30B
MRKMerck & Co., Inc.
$369.78B